Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy-Reference-Cited by-同舟云学术

Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Published:2021-11-01 Issue:9 Volume:37 Page:525-533
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Kim Jae Hui¹²,Kim Jong Woo¹,Kim Chul Gu¹

Affiliation:

1. Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.

2. Kim's Eye Hospital Data Center, Seoul, South Korea.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2021.0051

Reference33 articles.

1. Polypoidal Choroidal Vasculopathy

2. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times

3. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A rare case of very late recurrence of CSCR-induced CNVM following intra-articular injection of depot steroid;Indian Journal of Ophthalmology - Case Reports;2024-01

2. Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5;Frontiers in Medicine;2023-07-10

3. Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration;Graefe's Archive for Clinical and Experimental Ophthalmology;2023-06-14

4. Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization;Scientific Reports;2022-12-29